Table 1 Main characteristics of the controlled trials included in the meta-analysis
References | Type of study | Disease | Period of study | Intervention regimen | Control regimen | Participants | Median OS | HR (95% CI) | R0 (%) |
|---|---|---|---|---|---|---|---|---|---|
Hackert et al. | Retrospective | LAPC | 2001–2015 | Chemoradiotherapy | Chemotherapy | 322 vs 125 | 16.5 vs 16 | 0.93(0.67–1.28) | 31.3% vs 40.8% |
Shrestha et al. | Retrospective | BRPC | 2007–2012 | Chemoradiotherapy | Chemotherapy | 19 vs 14 | 16.4 vs 10.9 | 0.75(0.38–1.51) | NA |
Kim et al. | Retrospective | BRPC | 2007–2015 | Chemoradiotherapy | Chemotherapy | 25 vs 15 | 20.1 vs 16.1 | 0.67(0.26–1.72) | NA |
Satoi et al. | Prospective | BRPC/LAPC | 2008–2013 | Chemoradiotherapy | Chemotherapy | 35 vs 32 | 22 vs Not reached | 0.53(0.27–1.02) | 91% vs 81% |
Lloyd et al. | Retrospective | BRPC/LAPC | 2000–2013 | Chemoradiotherapy | Chemotherapy | 23 vs 65 | 12.5 vs 13.9 | 1.09(0.65–1.82) | 9% vs 6% |
Barbier et al. | Retrospective | LAPC | 1997–2006 | Chemoradiotherapy | Surgery-first | 88 vs 85 | 21.5 vs 18 | 1.16(0.7–1.91) | 92% vs 67% |
Casadei et al. | RCT | RPC/BRPC/LAPC | 2007–2014 | Chemoradiotherapy | Surgery-first | 18 vs 20 | 22.4 vs 19.5 | NA | 38.9% vs 25% |
Casadei et al. | Observtional | BRPC | 2000–2013 | Chemoradiotherapy | Surgery-first | 30 vs 28 | NA | NA | 93.3 vs 71.4% |
Fujii et al. | Observtional | BRPC | 2002–2014 | Chemoradiotherapy | Surgery-first | 21 vs 71 | 29.1 vs 13.1 | 0.28(0.10–0.75) a | 100% vs 40% |
Fujii et al. | Prospective | RPC/BRPC | 2001–2013 | Chemoradiotherapy | Surgery-first | 40 vs 233 | 28.6 vs 33.7 | 0.79(0.28–2.22) | 86% vs 70% |
Jang et al. | RCT | BRPC | 2012–2014 | Chemoradiotherapy | Surgery-first | 27 vs 23 | 21 vs 12 | 0.53(0.29–0.98) | 82.4% vs 33.3% |
Tafima et al. | Retrospective | RPC | 2006–2009 | Chemotherapy | Surgery-first | 13 vs 21 | NA | 1.18(0.43–3.24) | 84.6% vs 85.7% |
Golcher et al. | RCT | RPC | 2003–2009 | Chemoradiotherapy | Surgery-first | 33 vs 33 | 17.4 vs 14.4 | 0.96(0.55–1.67) | 89.5% vs 69.6% |
Murakami et al. | Retrospective | BRPC | 2002–2015 | Chemotherapy | Surgery-first | 52 vs 25 | 27.1 vs 11.6 | 0.42(0.25–0.72) | 72.3% vs 17.4% |